STRATA Skin Sciences Announces CMS Recognition of Expanded CPT Codes for Inflammatory and Autoimmune Dermatologic Conditions with Company Anticipating Wider Excimer Adoption Ahead Of 2027 CPT Expansion

Stock Information for Strata Skin Sciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Strata Skin Sciences Inc.

STRATA Skin Sciences Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
STRATA Skin Sciences to Report Third Quarter 2025 Financial Results on November 13, 2025 and Provide Corporate Update
STRATA Skin Sciences Announces COFEPRIS Clearance of TheraClear® in Mexico and First Commercial Placements
STRATA Skin Sciences Reinforces Market Leadership Following Key Litigation Milestones Against LaserOptek
Excimer Laser Demonstrates Promising Results in Treating Rare Variant of Cutaneous Lymphoma, Mycosis Fungoides
Marking Eczema Awareness Month - Clinical Research Validates Strata Skin Sciences' XTRAC® Excimer Laser as a Breakthrough Therapy for Localized Atopic Dermatitis
STRATA Skin Sciences Receives Continued Validation for its Personalized Approach with New Published Study Highlighting XTRAC® Excimer Laser Treatment Combined with a Topical Drug in Psoriasis
New Peer Reviewed Publication of Combination Therapy in Vitiligo with STRATA Skin Sciences' Excimer Laser and JAK Inhibitors Demonstrated Superior Safety and Unprecedented Response Rates, Providing Continued Validation of Personalized Medicine Approach

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.